Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRay [177Lu]-NeoB in GRPR-Positive Advanced Solid Tumors
2023-507170-41-00Phase 2Completed
- Sponsor
- Advanced Accelerator Applications
- Start
- Jul 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 6
01
Overview
Phase 2, open-label trial of neobomb1 in breast cancer, bronchial carcinoma, prostate cancer (PCa) and 3 more (5 arms), sponsored by Advanced Accelerator Applications. Primary endpoints: Incidence and nature of dose limiting toxicities (DLTs) and Individual clinical responses (RECIST v1.1 / RANO). Started Jul 2019; status: completed.
02
Drugs
neobomb1
03
Conditions
breast cancerbronchial carcinomaprostate cancer (PCa)gastrointestinal stromal tumor (GIST)glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-507170-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507170-41-00.